Immunicum AB (IMMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Immunicum AB (IMMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH314956D
  • |
  • Pages: 38
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Immunicum AB (Immunicum) is a biopharmaceutical company that focuses on the development of immuno-oncology therapies for the treatment of solid tumors. The company's lead development candidate, ilixadencel is in clinical trials for the treatment a range of solid tumors including hepatic cell carcinoma, renal cell carcinoma, and gastrointestinal stromal carcinoma. Its other pipeline programs include SUBCUVAX, Ad5PTDf35-Adenovirusvector and CD70 among others. Immunicum spans its expertise in the development of allogeneic, off-the-shelf cell-based therapies. The company works in partnership with academia, biotech and pharmaceutical companies to develop and commercialize new therapeutics. Immunicum is headquartered in Gothenburg, Sweden.

Immunicum AB (IMMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deal Details

Asset Purchase

Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million

Partnerships

Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership

Immunicum Enters into Research Agreement with Rutgers Cancer Institute

Equity Offering

Immunicum Raises USD24.2 Million in Rights Offering of Shares

Immunicum Raises USD15.5 Million in Right Offering of Shares

Immunicum Raises USD6.8 Million in Rights Offering of Shares

Immunicum Raises USD8.66 Million in Private Placement of Shares

Immunicum Completes IPO

Immunicum Announces Private Placement Of Shares For USD1.3 Million

Immunicum AB-Key Competitors

Immunicum AB-Key Employees

Immunicum AB-Locations And Subsidiaries

Head Office

Recent Developments

Financial Announcements

Feb 16, 2018: Immunicum Reports Net Loss Of TSEK18,826 In Fourth Quarter Of 2017

Nov 17, 2017: Immunicum Interim Report Q3-Corporate Update and Outlook

Aug 18, 2017: Immunicum: Interim Report Q2-Corporate Update and Outlook

May 19, 2017: Immunicum: Quarterly Report January-March 2017

Feb 17, 2017: Immunicum: Year-End Report 2016 (July 2016-December 2016)

Corporate Communications

Jan 31, 2018: Immunicum Appoints Michaela Gertz As CFO

Product News

06/12/2017: Immunicum Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX

Clinical Trials

Feb 14, 2017: Immunicum announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma

Other Significant Developments

Dec 04, 2017: Immunicum Announces Report from the Extraordinary General Meeting on December 4, 2017

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Immunicum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

List of Tables

Immunicum AB, Pharmaceuticals & Healthcare, Key Facts, 2016

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immunicum AB, Deals By Therapy Area, 2012 to YTD 2018

Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million

Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership

Immunicum Enters into Research Agreement with Rutgers Cancer Institute

Immunicum Raises USD24.2 Million in Rights Offering of Shares

Immunicum Raises USD15.5 Million in Right Offering of Shares

Immunicum Raises USD6.8 Million in Rights Offering of Shares

Immunicum Raises USD8.66 Million in Private Placement of Shares

Immunicum Completes IPO

Immunicum Announces Private Placement Of Shares For USD1.3 Million

Immunicum AB, Key Competitors

Immunicum AB, Key Employees

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16608
Site License
USD 500 INR 33215
Corporate User License
USD 750 INR 49823

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com